PDF(Pubmed)
Abstract：
We discuss a case of a 53-year-old woman with multiple sclerosis on monthly ofatumumab injections, who was infected with SARS-CoV-2 with persistent fevers for seven weeks. She was hospitalized for fever with diagnostic workup being unremarkable with negative SARS-CoV-2 IgM and undetectable nucleocapsid IgG antibodies four weeks out from the initial infection, indicating she may not have mounted an appropriate immune response to the infection. Patients on immunosuppression therapy may have a prolonged course of disease given that medications such as ofatumumab can take up to 24 weeks of B-cell recovery post-treatment discontinuation and a longer road to recovery.
摘要：
我们讨论了一个53岁的多发性硬化症患者，每月注射Ofatumumab，感染SARS-CoV-2并持续发烧7周。她因发烧而住院，诊断检查不明显，SARS-CoV-2IgM阴性，并且在初次感染后四周未检测到核衣壳IgG抗体，表明她可能没有对感染产生适当的免疫反应。考虑到诸如ofatumumab的药物在治疗停止后可能需要长达24周的B细胞恢复和更长的恢复道路，接受免疫抑制治疗的患者可能具有延长的病程。
